Almost everyone did not notice that the cumulative market value of the three CRISPR listed companies tripled between June 2017 and June 2018, with a cumulative market value of nearly $6 billion. However, in the past six months, the market value of these three companies has fallen by nearly… Continue Reading Progress of the latest clinical trials of 3 CRISPR listed companies

Nature Medicine conducted two CRISPR related articles on Monday. Both studies found that the CRISPR-Cas9 system can induce intracellular p53-mediated DNA damage and affect CRISPR genome editing. CRISPR-related companies’ share prices dropped sharply after the article went live, CRISPR Therapeutics fell nearly 13%, Editas Medicine fell nearly 8%, Intellia Therapeutics… Continue Reading Nature issued a document, the stock price dropped! How does p53 affect the future of CRISPR?

I In the spring of 2011, Jennifer Doudna of the University of California, Berkeley, travelled to Puerto Rico to attend the annual meeting of the American Microbiology Society. On the afternoon of the second day of the meeting, she went to a coffee shop with her friend John van der… Continue Reading The future is now: how CRISPR technology changes the world